Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prolastin for COPD Exacerbations
NCT07125664Phase 2Not yet recruiting
- Sponsor
- IRCCS San Matteo Foundation
- Start
- Oct 2025
- Primary completion
- Oct 2027
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of alpha-1-proteinase inhibitor in chronic obstructive pulmonary disease (COPD), sponsored by IRCCS San Matteo Foundation. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
alpha-1-proteinase inhibitor
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT07125664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07125664.